Management of chronic obstructive pulmonary disease (COPD), a complex, heterogeneous disease, has been complicated by new recommendations that incorporate novel escalation strategies with dual long-acting ß agonist (LABA)/long-acting muscarinic antagonist (LAMA) bronchodilation treatments and LAMA/LABA/inhaled corticosteroid (ICS) triple therapy. Dual bronchodilation and triple therapy treatment options are both now available as fixed-dose combination (FDC) inhalers. However, despite these updated recommendations and new inhaler options, limited practical guidance on individualizing therapy or identifying patients who may benefit from treatment escalation exists. In addition, lack of knowledge of appropriate COPD inhaler choice/use and self-management strategies persists, precluding optimal therapeutic benefit and clinical outcomes. This enduring interactive activity features 2 experts in COPD, who review and discuss advances in dual bronchodilation and triple drug inhalation therapy, the most recent COPD recommendations, as well as implementation of practical individualized treatment and inhaler strategies for patients with COPD.

The goal of this CE activity is for physicians, physician assistants, nurse practitioners, and nurses who manage patients with COPD in primary care settings to improve their knowledge base on COPD management strategies and related clinical guidelines and to translate this knowledge into optimizing individualized COPD treatment plans in practice.

This educational initiative is designed for primary care physicians, physician assistants, nurse practitioners, and nurses who manage patients with COPD.

After participating in this activity, participants will demonstrate an improved ability to:
  • DESCRIBE the most up-to-date scientific evidence supporting the use of inhaled maintenance therapies, including dual bronchodilation and ICS-containing regimens, for COPD.
  • EXPLAIN initial and escalation therapy recommendations for inhaled maintenance therapy based on the most recent COPD guidelines.
  • RECOGNIZE the symptoms and patient burden of COPD exacerbations, and the resulting need to escalate therapy.
  • SELECT appropriate initial and escalation inhaled maintenance treatment strategies based on patient symptoms, exacerbation risks, inhaler device, and clinical guidelines.
  • PROPOSE strategies that provide disease education and inhaler training to patients with COPD.
Release date: December 19, 2019
Expiration date: December 19, 2020
Estimated time to complete activity: 1.25 hours
Mechanism for the learner to contact PIM – (
Media: Internet

Joint Accreditation Statement
joint_provider_logoIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ASiM CE LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education – The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Barbara P. Yawn, MD, MSc, FAAFP (Chair)
Adjunct Professor
Department of Family and Community Health University of Minnesota
Minneapolis, Minnesota
Chief Science Officer of the COPD Foundation
Miami, Florida
Dr Yawn reports serving as a consultant on COPD-related advisory boards for AstraZeneca, Boehringer Ingelheim, and GlaxoSmithKline.

Stephen A. Brunton, MD
Executive Director
Primary Care Respiratory Group
Murrieta, California
Dr Brunton reports serving on a speakers bureau for AstraZeneca and serving on an advisory board for AstraZeneca, GlaxoSmithKline, and Mylan.

Featuring Patient Faculty Member John Linnell
State Captain, COPD Foundation
Mr Linnell reports serving as a consultant for AstraZeneca, Boehringer Ingelheim,GlaxoSmithKline, Propeller Health, and Verona Pharma plc; contracted research for GlaxoSmithKline.

The PIM planners and managers have nothing to disclose.

The following ASiM CE, LLC planners and managers, Jessica Marshall, PhD, and Jessica Epps, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Pentium 800 processor or greater, Windows 98/NT/200/XP or Mac OS 9/X or later, Microsoft Internet Explorer, Safari, Firefox, Windows Media Player 9.0 or later Flash player, 128 MB of RAM Monitor settings: High color at 800 x 600 pixels, Sound card and speakers, Adobe Acrobat Reader.

Method of Participation and Request for Credit
The following activity is an archive of a live symposium designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. In order to receive credit, please complete the preassessment, listen to and watch the presentations, complete and pass the postassessment with a score of at least 75%, and complete the evaluation to receive CME credit for this activity. A certificate of participation will be available online immediately following successful completion of the activity.

Introduction and Overview

Addressing Unmet Needs of COPD Patients:
One Size Does Not Fit All
Stephen A. Brunton, MD

Remaining Up-to-Date with COPD Treatment Guidelines and Pharmacotherapy Options – Case-Based Presentation
Barbara P. Yawn, MD, MSc, FAAFP

The Importance of the Inhaler: Improving Outcomes with Device Selection and Education
Stephen A. Brunton, MD

Conclusions and Postassessment
Barbara P. Yawn, MD, MSc, FAAFP

There is no fee for this educational activity.

Submit a case to review at meeting:

procced to pretest

MyCMESite is published by ASiM CE, LLC, d/b/a ASiM 166 W. Main Street, Somerville, NJ 08876. (908) 253-9001. Copyright ©2017 by ASiM CE, LLC. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. ASiM is a registered trademark of ASiM CE LLC. Contact Us